I assessed all 46 articles independently. Below are the scored articles, grouped by triage score tier for readability.

---

Articles 1–46: Scored Dimensions

Article 1 — Zhang et al., Lifestyle interventions for cardiometabolic health in PCOS (PMID 42854088)

Dimension	Score	Rationale
Scientific Novelty	4	Network meta-analysis approach adds some value over prior individual RCTs, but PCOS lifestyle intervention literature is well-trodden
Clinical Relevance	7	Directly informs clinical practice for a highly prevalent, undertreated condition; exercise dose guidance (480–1012 METs·min/week) is actionable
Population Reach	7	PCOS affects ~8–13% of reproductive-age women globally (hundreds of millions)
Implementation Speed	8	Exercise prescriptions require no new infrastructure; immediately integrable into clinical guidelines
Evidence Strength	6	Systematic review + network meta-analysis (n=2433); evidence certainty self-rated as low/very low; abstract only

• Quantitative result: 480–1012 METs·min/week associated with greatest overlap in predicted benefits across outcomes
• External validation: No independent replication; network meta-analysis aggregates existing trials
• Main limitation: Evidence certainty generally low or very low; heterogeneity in exercise protocols and outcomes
• Equity: Women with PCOS in low-income settings or without gym access may not benefit equally; home-based exercise may need emphasis
• Evidence Maturity: Validated ✓ (confirmed — synthesizes RCT-level evidence, but limited certainty)

---

Article 2 — Bueling et al., Diagnostic performance of screening tests for MACS in adrenal incidentalomas (PMID 42855136)

Dimension	Score	Rationale
Scientific Novelty	4	MACS-incidentaloma literature is active; hierarchical SROC meta-analysis is methodologically rigorous but not novel in topic
Clinical Relevance	6	Directly informs endocrinologists managing adrenal incidentalomas; cardiometabolic risk implications are real but diagnosis remains complex
Population Reach	5	Adrenal incidentalomas found in ~3–7% of CT scans; affected population is substantial but not universal
Implementation Speed	6	Existing biochemical tests; no new technology required, but results require clinical context
Evidence Strength	6	Systematic review + hierarchical SROC (n=1420); abstract only; standard meta-analytic quality ceiling

• Quantitative result: Not reported in abstract; specificity/sensitivity curves implied by SROC methodology
• External validation: Aggregates existing studies; not independently replicated
• Main limitation: Positive results require clinical context; performance varies by pre-test probability
• Equity: Incidentaloma detection biased toward populations with high CT imaging utilization
• Evidence Maturity: Validated ✓

---

Article 3 — Zheng et al., Home vs. centre exercise-based cardiac rehabilitation after CABG (PMID 42854284)

Dimension	Score	Rationale
Scientific Novelty	4	Home-based CR is an established alternative; this adds a CABG-specific meta-analytic lens
Clinical Relevance	6	Relevant to post-surgical care planning; conclusion is equivocal, limiting immediate impact
Population Reach	6	~500,000 CABG procedures annually in the US alone; globally significant
Implementation Speed	7	Home-based programs are already partially deployed; evidence supports expansion if equivalence confirmed
Evidence Strength	5	Small number of studies, substantial heterogeneity, inconclusive on psychosocial outcomes; n=991

• Quantitative result: No firm conclusions drawn; functional capacity outcomes uncertain
• External validation: None beyond pooled analysis
• Main limitation: Small study pool with high heterogeneity; no definitive conclusions on patient-reported outcomes
• Equity: Home-based CR could improve access for rural/low-mobility patients, but digital divide may limit uptake
• Evidence Maturity: Validated — downgrade to Exploratory given inconclusive findings; insufficient to confirm equivalence

---

Article 4 — Kuatov et al., Matching-adjusted indirect treatment comparisons in CIDP (PMID 42852926)

Dimension	Score	Rationale
Scientific Novelty	4	Methodological critique of existing ITCs; important for evidence quality but not a clinical discovery
Clinical Relevance	5	Improves reliability of comparative effectiveness decisions in CIDP; affects prescribers and payers
Population Reach	3	CIDP prevalence ~1–9 per 100,000; rare disease context elevates relative unmet need
Implementation Speed	5	Recommendations for future study design; no immediate clinical change
Evidence Strength	6	Systematic methodological review; transparent critique; abstract only

• Main limitation: No new efficacy data; identifies problems without definitively resolving treatment rankings
• Equity: Rare disease populations often underrepresented in trials; finding highlights need for better evidence
• Evidence Maturity: Validated ✓ (as methodological evidence)

---

Article 5 — Aalpona et al., Obese vs. lean PCOS: clinical, metabolic, hormonal profiles (PMID 42850789)

Dimension	Score	Rationale
Scientific Novelty	4	Confirms known obesity-PCOS interaction; PROSPERO-registered strengthens methodology
Clinical Relevance	6	Supports personalized management; lean PCOS burden finding has treatment implications
Population Reach	7	Directly relevant to hundreds of millions with PCOS worldwide
Implementation Speed	6	Reinforces existing personalized approach frameworks
Evidence Strength	6	Systematic review/meta-analysis (n=5363); abstract only

• Main limitation: Only abstract available; heterogeneity across included studies likely
• Equity: Lean PCOS patients historically undertreated/unrecognized — finding supports equity improvement
• Evidence Maturity: Validated ✓

---

Article 6 — Inban et al., GLP-1 drugs for substance use disorders (PMID 42855378)

Dimension	Score	Rationale
Scientific Novelty	6	Repurposing GLP-1RAs for SUD is genuinely novel; growing but not yet mainstream evidence base
Clinical Relevance	6	Potentially addresses a massive unmet need; evidence currently observational only
Population Reach	8	SUD affects hundreds of millions globally across multiple substances
Implementation Speed	5	GLP-1RAs already approved for metabolic indications; off-label SUD use possible but premature
Evidence Strength	5	Systematic review of predominantly observational data; no RCTs included per abstract

• Quantitative result: "Good potential protective properties" — no effect size reported
• Main limitation: Evidence base is observational; causality not established; no head-to-head RCTs
• Equity: SUD disproportionately affects lower-income populations who may lack access to expensive GLP-1RAs
• Evidence Maturity: Validated — revise to Exploratory given observational-only base

---

Article 7 — Crees et al., Conditioning for autologous hematopoietic stem cell gene therapies (PMID 42855377)

Dimension	Score	Rationale
Scientific Novelty	6	Discusses emerging conditioning regimens for approved and investigational gene therapies; timely synthesis
Clinical Relevance	5	Relevant to transplant specialists and gene therapy programs; indirect for most clinicians
Population Reach	4	Targets rare nonmalignant blood diseases; small absolute population, high unmet need
Implementation Speed	3	Novel conditioning strategies require significant validation before adoption
Evidence Strength	4	Narrative review/expert perspective; no original data; medium classification confidence

• Main limitation: Exploratory synthesis; no clinical trial data presented
• Equity: Gene therapies currently extremely expensive and geographically concentrated
• Evidence Maturity: Exploratory ✓

---

Article 8 — Varghese et al., Weight management in obesity-associated sleep-disordered breathing (PMID 42855133)

Dimension	Score	Rationale
Scientific Novelty	3	Mechanistic review; established concepts with updated framing around GLP-1/phenotype-informed management
Clinical Relevance	5	Practical review for endocrinologists and sleep medicine specialists
Population Reach	7	OSA affects ~936 million adults worldwide
Implementation Speed	5	Guidance requires phenotyping infrastructure; GLP-1 options partially available
Evidence Strength	4	Narrative review; no original data; medium confidence

• Evidence Maturity: Revise to Exploratory (narrative review, no original evidence)

---

Article 9 — Ng et al., International consensus on retinal vein occlusion (PMID 42854985)

Dimension	Score	Rationale
Scientific Novelty	4	Updated consensus; incorporates AI, new anti-VEGF agents, drug delivery systems
Clinical Relevance	7	Major international guideline; directly shapes ophthalmologic practice across Asia-Pacific and beyond
Population Reach	6	RVO affects ~16 million people globally
Implementation Speed	6	Consensus statements adoptable relatively quickly by ophthalmology practices
Evidence Strength	5	Expert consensus; no original data; 35+ international authors lend credibility

• Main limitation: Consensus document, not primary evidence; potential for expert disagreement
• Equity: Asia-Pacific focus; recommendations may not translate equally to other health system contexts
• Evidence Maturity: Revise to Exploratory (consensus, not empirically validated guideline)

---

Article 10 — Zhang et al., Knowledge-guided multimodal learning for pCR prediction in breast cancer (PMID 42854913)

Dimension	Score	Rationale
Scientific Novelty	6	Combining pathology images + clinical data with knowledge-guided architecture is novel; interpretability focus is valuable
Clinical Relevance	6	Pretreatment pCR prediction could guide neoadjuvant decisions; framework stage only
Population Reach	7	Breast cancer is the world's most common cancer; neoadjuvant chemotherapy widely used
Implementation Speed	4	Requires prospective validation and regulatory pathways before clinical use
Evidence Strength	6	Observational/cohort (n=1486); internal validation implied; no external validation confirmed; medium confidence

• Main limitation: No external validation cohort confirmed; abstract only; retrospective design
• Equity: Pathology digitization infrastructure required; may disadvantage lower-resource settings
• Evidence Maturity: Validated — confirm with caveat (internal validation only)

---

Article 11 — Ulanski et al., Diabetic retinopathy in Hispanic/Latino adults (PMID 42854854)

Dimension	Score	Rationale
Scientific Novelty	4	Contemporary prevalence estimates in a specific ethnic group; hypertension-DR link well-known
Clinical Relevance	5	Supports targeted screening programs; hypertension control emphasis is actionable
Population Reach	6	62+ million Hispanic/Latino adults in the US; globally relevant to Latin American populations
Implementation Speed	6	Blood pressure control is an existing, scalable intervention
Evidence Strength	5	Multicenter (n=1224); cross-sectional; medium confidence; single ethnic group limits generalizability

• Equity: 🟡 Important equity lens — directly studies an underserved, higher-burden population
• Evidence Maturity: Revise to Exploratory (cross-sectional, single ethnic population, abstract only)

---

Article 12 — Nothnick et al., miRNAs as non-invasive diagnostic markers for endometriosis (PMID 42854833)

Dimension	Score	Rationale
Scientific Novelty	5	10-year update; highlights methodological inconsistencies preventing consensus — itself a useful finding
Clinical Relevance	6	Endometriosis diagnosis often delayed 7–10 years; a validated blood test would transform care
Population Reach	7	~190 million women affected by endometriosis worldwide
Implementation Speed	3	Lack of methodological consensus means no near-term clinical tool; standardization needed first
Evidence Strength	5	Meta-analysis; narrative framing; high classification confidence but abstract only

• Main limitation: No consensus miRNA signature identified; methodological heterogeneity across studies is the central finding
• Equity: Diagnostic delays disproportionately affect younger women and those with limited specialist access
• Evidence Maturity: Revise from Potentially Practice-Changing to Exploratory — the review demonstrates consensus has NOT been reached

---

Article 13 — Nakamura et al., Nivolumab in ctDNA-defined bTMB-High advanced solid tumors (Phase II) (PMID 42854587)

Dimension	Score	Rationale
Scientific Novelty	7	First prospective signal for ctDNA-based bTMB as a tumor-agnostic biomarker for nivolumab selection; genuinely novel
Clinical Relevance	7	Could enable liquid biopsy-guided immunotherapy selection without tissue; high unmet need in late-line GI cancers
Population Reach	6	Advanced solid tumor patients broadly; GI cancer focus narrows but adds specificity
Implementation Speed	4	Small n=28; requires validation in larger RCTs before adoption
Evidence Strength	5	Phase II, n=28 (very small); no randomization; medium confidence; prespecified hypothesis a strength

• Quantitative result: ORR in bTMB-High cohort — specific value not reported in abstract
• External validation: Not yet validated; explicitly calls for larger RCTs
• Main limitation: Very small sample (n=28); single-arm; GI cancer-heavy cohort
• Equity: Liquid biopsy access may be limited in low-resource settings; tissue biopsy access inequities make this potentially democratizing
• Evidence Maturity: Confirmed as Validated (prospective Phase II with prespecified endpoint), but very preliminary

---

Article 14 — Liu et al., DNAzyme nanoamplifier for piRNA imaging and gene therapy (PMID 42854433)

Dimension	Score	Rationale
Scientific Novelty	7	Innovative CCD-circuit DNAzyme design; novel detection amplification mechanism
Clinical Relevance	2	Preclinical technology; no human clinical data
Population Reach	3	Highly speculative at this stage
Implementation Speed	2	Years from clinical translation
Evidence Strength	3	Technology proof-of-concept; no human validation

• Evidence Maturity: Exploratory ✓

---

Article 15 — Abazie et al., Prognostic significance of isolated LBBB in patients with chest pain (PMID 42854282)

Dimension	Score	Rationale
Scientific Novelty	5	Isolated LBBB prognostic data in cardiometabolic-naive patients is undercharacterized
Clinical Relevance	6	Large real-world cohort; directly informs ED/outpatient risk stratification
Population Reach	6	LBBB prevalence ~0.5–1% of ECGs; chest pain presentations universal
Implementation Speed	7	ECG-based; no new technology required; workflow integration feasible
Evidence Strength	6	Large observational cohort (n=12,035); medium confidence; retrospective limitations

• Main limitation: Observational; confounding possible; abstract only; causality not established
• Evidence Maturity: Validated ✓

---

Article 16 — Nguyen et al., AI/ML evidence integrity in spine surgery (PMID 42854258)

Dimension	Score	Rationale
Scientific Novelty	5	Spin/bias analysis of AI evidence is methodologically important; adds to growing evidence quality literature
Clinical Relevance	5	Relevant to journal editors, systematic reviewers, and clinicians interpreting AI spine literature
Population Reach	4	Spine surgery patient population is large; direct patient impact is indirect
Implementation Speed	5	Reporting standard improvements could be adopted relatively quickly by journals
Evidence Strength	6	Systematic review with critical appraisal; high confidence; abstract only

• Evidence Maturity: Validated ✓

---

Article 17 — Lozhkina et al., AI-based individualized therapy optimization for T2D (PMID 42854216)

Dimension	Score	Rationale
Scientific Novelty	6	AI outperforming guidelines in complex T2D cases is noteworthy; multi-source integration is relatively novel
Clinical Relevance	6	If validated prospectively, could meaningfully improve complex T2D management
Population Reach	8	T2D affects ~540 million adults globally
Implementation Speed	4	Retrospective validation only; prospective RCT needed before implementation
Evidence Strength	4	Retrospective, n=533, internal validation only; medium confidence

• Main limitation: Retrospective; small n; internal validation; "limited number of patients" acknowledged by authors
• Evidence Maturity: Confirmed Validated — but note this is retrospective internal validation only; Exploratory more appropriate for translation purposes

---

Article 18 — Wang et al., Sodium bicarbonate + sprint interval training in basketball players (PMID 42853711)

Dimension	Score	Rationale
Scientific Novelty	5	Dose-dependent effect of sodium bicarbonate with SIT is novel; ergogenic literature is niche
Clinical Relevance	2	No clinical/disease relevance; sports performance only
Population Reach	2	Competitive basketball players; very narrow population
Implementation Speed	6	Supplement is cheap and available; but GI tolerability is a barrier
Evidence Strength	4	RCT design is a strength; n=10 is critically underpowered; abstract only

• Evidence Maturity: Revise from Potentially Practice-Changing to Exploratory (n=10 RCT)

---

Article 19 — Zhang et al., Chinese visceral adiposity index and hypertension in rural elderly (PMID 42853626)

Dimension	Score	Rationale
Scientific Novelty	4	CVAI-hypertension association adds to existing adiposity-BP literature; rural elderly focus is useful
Clinical Relevance	4	Cross-sectional; association does not confirm CVAI as clinically useful screening tool alone
Population Reach	5	Rural elderly Chinese population is large; generalizability to other groups unclear
Implementation Speed	5	CVAI calculation is simple; screening application needs prospective evidence
Evidence Strength	4	Cross-sectional (n=3280); medium confidence; abstract only

• Evidence Maturity: Exploratory ✓

---

Article 20 — Salvadó et al., APOE-ε4, sex, and medial temporal tau in Alzheimer's (PMID 42853420)

Dimension	Score	Rationale
Scientific Novelty	7	Distinguishing APOE-ε4 vs. sex-specific tau pathways with amyloid-independent mechanisms in women is a meaningful mechanistic advance
Clinical Relevance	5	Mechanistic insight; no immediate treatment change but informs sex-stratified trial design
Population Reach	8	Alzheimer's disease affects 55+ million globally; sex and APOE biology highly relevant
Implementation Speed	3	Basic science/neuropathology finding; translation timeline is long
Evidence Strength	7	Large two-cohort neuropathological study (n=2550, ROS/MAP + AZSAND replication); well-designed

• Main limitation: Post-mortem neuropathology; not directly translatable to living patients; medium confidence
• Equity: Women disproportionately affected by AD; finding supports sex-stratified research equity
• Evidence Maturity: Validated ✓

---

Article 21 — Wavreil et al., Directing mutant huntingtin towards degradation in HD (PMID 42852943)

Dimension	Score	Rationale
Scientific Novelty	5	Ubiquitin-targeting strategies for mHTT are active area; review synthesizes emerging approaches
Clinical Relevance	4	No approved therapy yet; preclinical stage
Population Reach	3	HD affects ~30,000 in US, ~300,000 globally; high unmet need
Implementation Speed	2	Years from clinical translation
Evidence Strength	3	Narrative review; no original data

• Evidence Maturity: Exploratory ✓

---

Article 22 — Guo et al., Intergenerational educational mobility and intrinsic capacity in aging (PMID 42852608)

Dimension	Score	Rationale
Scientific Novelty	5	Cross-country harmonized analysis of IEM and WHO intrinsic capacity framework is methodologically innovative
Clinical Relevance	4	Public health/policy relevance; limited direct clinical application
Population Reach	7	Aging globally; 5-country analysis strengthens generalizability
Implementation Speed	3	Policy changes in education operate on generational timescales
Evidence Strength	5	Meta-analysis; high confidence; abstract only

• Evidence Maturity: Confirm Potentially Practice-Changing — context-dependent; more apt as Validated for policy relevance

---

Article 23 — Dar et al., Stiff-Person Syndrome: comprehensive review (PMID 42852333)

Note: DOI resolves to BMC Neurology, not Yale Journal of Biology — possible metadata error in source

Dimension	Score	Rationale
Scientific Novelty	4	Comprehensive review of a rare condition; highlights diagnostic challenges and emerging immunotherapeutics
Clinical Relevance	5	Useful for neurologists; electrophysiological validation guidance is actionable
Population Reach	2	SPS prevalence ~1-2 per million
Implementation Speed	4	Electrophysiological testing already available; biomarker testing accessible in reference labs
Evidence Strength	3	Narrative review; no original data; medium confidence

• Evidence Maturity: Exploratory ✓

---

Article 24 — Nair & Mistry, Rare diseases as engines of biomedical innovation (PMID 42852022)

Note: DOI prefix suggests Nature Reviews Neurology, not Yale Journal — possible metadata discrepancy

Dimension	Score	Rationale
Scientific Novelty	4	Conceptual/advocacy piece; makes an important argument about research standards
Clinical Relevance	3	Indirect; policy and research design implications
Population Reach	5	Conceptual impact across rare disease community globally
Implementation Speed	3	Culture/policy change is slow
Evidence Strength	3	Review/opinion; no original data

• Evidence Maturity: Exploratory ✓

---

Article 25 — Chinese Society of Pathology, Expert consensus on cfDNA NGS for tumor driver genes (PMID 42851191)

Dimension	Score	Rationale
Scientific Novelty	4	Chinese national consensus; standardization contribution rather than scientific discovery
Clinical Relevance	6	Operationalizes cfDNA testing in China; consensus documents drive adoption
Population Reach	7	Enormous cancer burden in China; relevant globally for liquid biopsy standardization
Implementation Speed	6	Consensus issued; implementation can begin immediately in compliant institutions
Evidence Strength	4	Consensus document; no original data; Chinese language limits global accessibility

• Evidence Maturity: Exploratory ✓ (consensus, not empirically derived)

---

Article 26 — Liu et al., Focused ultrasound and liquid biopsy for glioma (PMID 42855393)

Dimension	Score	Rationale
Scientific Novelty	6	Convergence of FUS + liquid biopsy + AI for glioma is conceptually exciting and relatively novel
Clinical Relevance	4	Review/conceptual; no clinical outcome data
Population Reach	4	Glioma ~3 per 100,000; small absolute population but very high unmet need
Implementation Speed	2	FUS-enhanced BBB opening for biomarker release is still experimental
Evidence Strength	3	Narrative review; medium confidence

• Evidence Maturity: Exploratory ✓

---

Article 27 — Xu et al., Onco-fetal reprogramming and drug resistance via single-cell transcriptomics (PMID 42855278)

Dimension	Score	Rationale
Scientific Novelty	7	Single-cell identification of onco-fetal cancer subpopulation with defined transcription factor drivers (PTMA, ATF5, TCF4, FOS) is genuinely novel
Clinical Relevance	3	Preclinical discovery; no immediate clinical application
Population Reach	4	Pan-cancer relevance possible but tumor-specific findings initially
Implementation Speed	2	Basic science; long translation timeline
Evidence Strength	5	Single-cell genomics study; human tissue; no sample size reported; medium confidence

• Evidence Maturity: Exploratory ✓

---

Article 28 — Paspulati & Ronen, Imaging review of small bowel pathologies (PMID 42855204)

Dimension	Score	Rationale
Scientific Novelty	3	Educational imaging review; no new data
Clinical Relevance	4	Useful reference for radiologists; not practice-changing
Population Reach	3	Small bowel tumors are uncommon
Implementation Speed	5	Awareness-raising; directly applicable to radiology practice
Evidence Strength	3	Narrative review; no original data

• Evidence Maturity: Exploratory ✓

---

Article 29 — Gao et al., AI-assisted multi-omics for stroke risk in hypertension (PMID 42855111)

Dimension	Score	Rationale
Scientific Novelty	5	Multi-omics + AI for stroke risk is emerging; conceptual review
Clinical Relevance	4	Promising framework; no validated clinical tool
Population Reach	7	Hypertension affects 1.3 billion globally; stroke is leading cause of disability
Implementation Speed	3	Multi-omics infrastructure not widely available
Evidence Strength	3	Review; no original data; medium confidence

• Evidence Maturity: Exploratory ✓

---

Article 30 — Wu et al., GWAS of osteoarthritis: from discovery to precision medicine (PMID 42855042)

Dimension	Score	Rationale
Scientific Novelty	5	Synthesizes GWAS findings for OA with precision medicine lens; highlights translation gaps
Clinical Relevance	4	No disease-modifying therapy available; pathway identification step
Population Reach	8	OA affects >500 million people worldwide
Implementation Speed	2	GWAS to therapy translation is a decade-scale challenge
Evidence Strength	4	Review; no original data; medium confidence

• Evidence Maturity: Exploratory ✓

---

Article 31 — Jing et al., Circular RNAs in breast cancer immunometabolism (PMID 42854996)

Dimension	Score	Rationale
Scientific Novelty	5	circRNA-immunometabolism intersection in breast cancer is an emerging, active area
Clinical Relevance	3	Mechanistic review; preclinical targets only
Population Reach	6	Breast cancer is the most common cancer globally
Implementation Speed	2	Basic science; translation years away
Evidence Strength	3	Review; medium confidence

• Evidence Maturity: Exploratory ✓

---

Article 32 — Tversky et al., Dupilumab for CRSsNP (Phase II RCT) (PMID 42854988)

Dimension	Score	Rationale
Scientific Novelty	6	Dupilumab approved for CRSwNP; extension to CRSsNP (the harder population) is clinically meaningful and novel
Clinical Relevance	7	Phase II RCT showing patient-reported improvement in a condition affecting ~8% of population
Population Reach	7	CRSsNP affects up to 8% of the population (~640 million people)
Implementation Speed	5	Dupilumab is already marketed; off-label use possible; Phase III needed for approval
Evidence Strength	5	Randomized double-blind placebo-controlled Phase II; sample size not reported in abstract; medium confidence

• Main limitation: Sample size not in abstract; Phase II only; no long-term outcomes
• Equity: Dupilumab is expensive; access inequities likely
• Evidence Maturity: Revise from Exploratory to Validated (RCT design confirmed)

---

Article 33 — Yuzuguldu et al., Urolithiasis in pediatric ALL/LLy (PMID 42854217)

Dimension	Score	Rationale
Scientific Novelty	5	Underrecognized complication; systematic documentation adds clinical value
Clinical Relevance	5	Relevant to pediatric oncology; glucocorticoid-exposed patients should be monitored
Population Reach	3	Pediatric ALL is the most common childhood cancer; stone complication is a subset
Implementation Speed	6	Monitoring protocols can be implemented immediately
Evidence Strength	3	Case series; no sample size reported; single center; medium confidence

• Evidence Maturity: Exploratory ✓

---

Article 34 — Li et al., Global trends in esophageal cancer burden 1990–2021 (PMID 42854076)

Dimension	Score	Rationale
Scientific Novelty	4	GBD-based analysis; standardized rates declining despite rising absolute burden
Clinical Relevance	4	Public health relevance; limited direct clinical change
Population Reach	6	Esophageal cancer is 6th leading cause of cancer mortality worldwide
Implementation Speed	4	Policy-level changes
Evidence Strength	5	GBD 2021 dataset; observational; medium confidence

• Evidence Maturity: Validated ✓

---

Article 35 — Huang et al., Gout burden among middle-aged Chinese adults, GBD 2023 (PMID 42854061)

Dimension	Score	Rationale
Scientific Novelty	4	GBD-based projection; important for public health planning but not scientifically novel
Clinical Relevance	3	Epidemiological; limited direct clinical change
Population Reach	5	Middle-aged Chinese adults — large group; gout prevalence increasing
Implementation Speed	3	Population-level policy
Evidence Strength	5	GBD modeled estimates; medium confidence; ecological analysis

• Evidence Maturity: Validated ✓

---

Article 36 — Liao et al., Shared genetic architecture between constipation and aging phenotypes (PMID 42854059)

Dimension	Score	Rationale
Scientific Novelty	5	Cross-trait GWAS linking constipation to aging-related phenotypes is novel; CNS enrichment finding interesting
Clinical Relevance	3	Basic genetics finding; no immediate clinical application
Population Reach	6	Constipation highly prevalent in older adults
Implementation Speed	2	Functional investigation needed first
Evidence Strength	4	GWAS-based cross-trait analysis; no sample size; medium confidence

• Evidence Maturity: Exploratory ✓

---

Article 37 — Fang et al., SF3B1-mutated MDS coexisting with β-thalassemia trait (PMID 42854053)

Dimension	Score	Rationale
Scientific Novelty	5	Rare co-occurrence with diagnostic implications; molecular testing approach for distinction is clinically useful
Clinical Relevance	5	Relevant to hematologists managing MDS with microcytosis
Population Reach	2	Very rare specific combination
Implementation Speed	5	Molecular testing already available
Evidence Strength	2	Single case report with literature review; no prevalence estimate possible

• Evidence Maturity: Exploratory ✓

---

Article 38 — Liu et al., IGF2BP1 cooperates with MYCN in neuroblastoma via purine biosynthesis (PMID 42853659)

Dimension	Score	Rationale
Scientific Novelty	7	CRISPR screen identifying IGF2BP1-PAICS axis in 17q-gain/MYCN-amp neuroblastoma is mechanistically significant
Clinical Relevance	3	Preclinical (PNAS); no clinical data yet; PAICS as a therapeutic target is novel
Population Reach	3	Neuroblastoma is rare; 17q+/MYCN-amp subset is a fraction of that
Implementation Speed	2	Years to clinical translation
Evidence Strength	5	CRISPR functional screen + PAICS mechanistic validation; human cell lines and likely animal models; medium confidence

• Evidence Maturity: Exploratory ✓

---

Article 39 — Yu et al., piRNAs in cancer: comprehensive landscape (PMID 42852637)

Dimension	Score	Rationale
Scientific Novelty	4	Comprehensive piRNA cancer review; nanodelivery and sequencing integration is timely
Clinical Relevance	3	Exploratory; no clinical translation yet
Population Reach	5	Pan-cancer relevance
Implementation Speed	2	Technology-dependent
Evidence Strength	3	Review; medium confidence

• Evidence Maturity: Exploratory ✓

---

Article 40 — Chen et al., cGAS-STING pathway in digestive tract cancer (PMID 42852635)

Dimension	Score	Rationale
Scientific Novelty	5	cGAS-STING as dual suppressor/promoter in GI cancers is a nuanced and developing finding
Clinical Relevance	4	Mechanistic; therapeutic implications are years away
Population Reach	6	GI cancers are the most common cancer type globally
Implementation Speed	2	Preclinical
Evidence Strength	3	Review; medium confidence

• Evidence Maturity: Exploratory ✓

---

Article 41 — Lu et al., BTK inhibitor resistance in DLBCL (PMID 42852632)

Dimension	Score	Rationale
Scientific Novelty	5	BTKi resistance mechanisms in DLBCL specifically (not CLL) are less studied; actionable for combination therapy design
Clinical Relevance	5	Relevant to oncologists managing relapsed/refractory DLBCL
Population Reach	4	DLBCL is the most common lymphoma globally
Implementation Speed	3	Biomarker development and combination trials needed
Evidence Strength	3	Review; medium confidence

• Evidence Maturity: Exploratory ✓

---

Article 42 — Beiriger et al., TTMV-HPV DNA in hypopharyngeal squamous cell carcinoma (PMID 42852307)

Note: DOI resolves to a 2013 JAMA Otolaryngology paper — likely a metadata error; actual article may be newer

Dimension	Score	Rationale
Scientific Novelty	5	Extending TTMV-HPV DNA detection to hypopharyngeal SCC (beyond oropharynx) is novel
Clinical Relevance	5	Case report demonstrating surveillance utility; relevant to head and neck oncology
Population Reach	3	Hypopharyngeal SCC is rare; p16-positive subset even smaller
Implementation Speed	5	TTMV-HPV DNA assay commercially available; adoption feasible
Evidence Strength	2	Single case report; no generalizable data

• Evidence Maturity: Exploratory ✓

---

Article 43 — Bakken et al., Recovery from CFS — healthcare professional perspectives (PMID 42853299)

Dimension	Score	Rationale
Scientific Novelty	3	Qualitative; describes HCP frameworks for CFS recovery; contested clinical field
Clinical Relevance	4	Relevant to ME/CFS treatment context; qualitative findings support therapeutic alliance
Population Reach	5	ME/CFS affects ~0.5–1% of the population; highly disabling
Implementation Speed	4	Attitudinal/behavioral change; no new technology
Evidence Strength	3	Qualitative; small cohort; medium confidence

• Evidence Maturity: Exploratory ✓

---

Article 44 — Nahok et al., Functional thiamine deficiency in CKD patients, Northeast Thailand (PMID 42852733)

Dimension	Score	Rationale
Scientific Novelty	4	Hypertension as independent predictor of thiamine deficiency in CKD is a novel association
Clinical Relevance	4	Screening implications for CKD-hypertension overlap; interventional evidence lacking
Population Reach	5	CKD affects ~850 million globally; thiamine deficiency subset unclear
Implementation Speed	5	Thiamine testing is cheap; but supplementation needs RCT evidence
Evidence Strength	4	Cross-sectional (n=605); adjusted multivariate analysis is a strength; single geographic region

• Evidence Maturity: Exploratory ✓

---

Article 45 — Boronbaev et al., Oncological disease burden in Osh Oblast, Kyrgyzstan (PMID 42850864)

Dimension	Score	Rationale
Scientific Novelty	2	Regional epidemiological surveillance; no novel methodology
Clinical Relevance	2	Regional cancer care planning; no clinical innovation
Population Reach	2	Osh Oblast, Kyrgyzstan — limited geographic scope
Implementation Speed	3	Awareness-raising for regional health authorities
Evidence Strength	3	Descriptive regional data; medium confidence

• Evidence Maturity: Exploratory ✓

---

Article 46 — Bodunova et al., Dynamic surveillance for cancer detection in high-risk genetic carriers (PMID 42850863)

Dimension	Score	Rationale
Scientific Novelty	5	Multidisciplinary routing model for germline variant carriers is clinically relevant organizational innovation
Clinical Relevance	5	Could inform surveillance program design globally
Population Reach	5	Hereditary cancer risk carriers — growing population as genetic testing expands
Implementation Speed	4	Requires multidisciplinary team setup; prototype stage
Evidence Strength	3	Descriptive organizational study; no outcomes reported; medium confidence

• Evidence Maturity: Exploratory ✓

---

---

Conflict Notes

Methodological conflict (Articles 1, 5, 6 — PCOS/cardiometabolic cluster): Articles 1 and 5 both address PCOS, with Article 1 advocating exercise and Article 5 emphasizing obesity-phenotype heterogeneity. These are complementary rather than conflicting, but together suggest a nuanced treatment landscape where one-size exercise prescriptions may inadequately account for metabolic subtype. Article 6 (GLP-1 for SUD) is in an entirely different domain with weaker evidence.

GLP-1/weight management tension (Articles 6, 8): Article 8 synthesizes obesity-SDB management including GLP-1, while Article 6 ventures into SUD. No direct conflict, but they represent different maturity levels of GLP-1 repurposing evidence.

AI evidence quality concern (Article 16): The systematic review documenting spin in AI spine surgery literature is a cautionary signal for ALL AI/ML articles in this batch (Articles 10, 17, 29). Readers should apply heightened scrutiny to AI-driven clinical claims without external validation.

---

Ranked Impact Table

Rank	Article #	PMID	Title (short)	Flag	Impact Score	Clinical Relevance (30%)	Population Reach (25%)	Scientific Novelty (20%)	Implementation Speed (15%)	Evidence Strength (10%)	Triage Score (OpenClaw)	Study Design	Rank Justification
1	1	42854088	Lifestyle interventions for cardiometabolic health in PCOS	🟢	6.55	7	7	4	8	6	9	Systematic Review / NMA	Directly actionable exercise dose guidance (480–1012 METs·min/week) for a condition affecting hundreds of millions of women, synthesized from a large network meta-analysis (n=2,433). Evidence certainty is the limiting factor, but the intervention requires no new technology, no new drugs, and no regulatory approval — making implementation speed the highest in the batch.
2	32	42854988	Dupilumab for CRSsNP (Phase II RCT)	⚪	6.35	7	7	6	5	5	6	Phase II RCT	First randomized evidence that dupilumab improves patient-reported outcomes in CRSsNP — the larger, harder-to-treat form of chronic sinusitis affecting ~8% of the population. Dupilumab is already approved and marketed for related conditions, reducing regulatory barriers for potential expanded indication. Phase II size and abstract-only access prevent higher ranking.
3	13	42854587	Nivolumab in ctDNA-defined bTMB-High tumors (Phase II)	⚪	6.15	7	6	7	4	5	7	Phase II prospective	The first prospective signal supporting ctDNA-based blood TMB as a tumor-agnostic immunotherapy selection biomarker. If validated, this could enable liquid biopsy-guided checkpoint inhibitor prescribing without tissue biopsy — a meaningful advance for patients with inaccessible tumors. The n=28 limits confidence severely; larger randomized trials are explicitly required.
4	5	42850789	Obese vs. lean PCOS: clinical, metabolic, hormonal profiles	⬜	6.00	6	7	4	6	6	8	Systematic Review / MA	Large PROSPERO-registered meta-analysis (n=5,363) confirming that lean PCOS carries substantial reproductive/metabolic burden, supporting personalized management beyond obesity-focused strategies. Clinically actionable for practitioners managing lean PCOS patients who are often undertreated.
5	10	42854913	Multimodal AI for pCR prediction in breast cancer	⚪	5.90	6	7	6	4	6	7	Cohort (n=1,486)	Knowledge-guided multimodal AI combining pathology images and clinical data in the largest cohort of this type for pCR prediction. Internal validation on 1,486 patients is encouraging; external validation is the missing piece before clinical adoption. Strong breast cancer population reach elevates this despite its framework-stage status.
6	20	42853420	APOE-ε4 and sex drive distinct tau pathways in AD	⚪	5.80	5	8	7	3	7	7	Two-cohort neuropathology (n=2,550)	Largest neuropathological cohort study identifying sex-specific, amyloid-independent tau mechanisms in women with Alzheimer's disease. The replication cohort (AZSAND, n=963) significantly strengthens credibility. Though translation is slow (post-mortem biology), the mechanistic finding directly informs why sex-stratified trial designs are essential for next-generation AD therapies.
7	3	42854284	Home vs. centre cardiac rehab after CABG	🟢	5.75	6	6	4	7	5	8	Systematic Review / MA	Home-based CR equivalence vs. centre-based remains unconfirmed in this CABG-specific meta-analysis (n=991), but the equivocal finding is itself clinically important: it cautions against wholesale home-CR adoption without better evidence, while encouraging further research. Immediate implementation value is in steering clinician and policy conversations toward rigorous HBCR trial design.
8	6	42855378	GLP-1 drugs for substance use disorders	⚪	5.70	6	8	6	5	5	7	Systematic Review	Strong population reach (SUD affects hundreds of millions globally) and genuine novelty in repurposing GLP-1RAs, but the entire evidence base is observational. No head-to-head RCTs. Ranked lower than its population reach would suggest because implementation of GLP-1s for SUD cannot be responsibly recommended without controlled trial evidence.
9	15	42854282	LBBB predicts MI and HF in chest pain patients without prior heart disease	⚪	5.70	6	6	5	7	6	7	Cohort (n=12,035)	Large real-world cohort demonstrating isolated LBBB is an independent predictor of MI, HF, and heart disease in patients without prior cardiometabolic disease. ECG-based risk stratification is immediately integrable into existing workflows; no new tools needed. Retrospective design and abstract-only status are limiting.
10	2	42855136	Biochemical screening for MACS in adrenal incidentalomas	⬜	5.65	6	5	4	6	6	8	Systematic Review / SROC MA	Methodologically sophisticated SROC meta-analysis informing endocrinologists on biochemical test performance for MACS in adrenal incidentalomas. Clinically actionable within endocrinology practice but limited by absence of a clearly superior test and requirement for clinical context with all results.
11	9	42854985	International consensus on retinal vein occlusion	⚪	5.50	7	6	4	6	5	7	International Consensus	Major international guideline update integrating AI, new anti-VEGF agents, and drug delivery systems for RVO. High clinical relevance for ophthalmology; ranked here because it is expert consensus rather than new primary evidence.
12	12	42854833	miRNAs as non-invasive markers for endometriosis	⚪	5.45	6	7	5	3	5	7	Meta-analysis	Despite massive potential reach (190M affected), the review's central finding — that methodological heterogeneity prevents consensus — is honest and important but clinically frustrating. Implementation speed is low because the field needs standardization first. Ranked to highlight the unmet need.
13	38	42853659	IGF2BP1-MYCN cooperation via purine biosynthesis in neuroblastoma	⚪	4.15	3	3	7	2	5	6	CRISPR functional screen	Highest scientific novelty score for a preclinical study in this batch; CRISPR-identified PAICS target in a dangerous neuroblastoma subset is mechanistically important. Low clinical relevance and implementation speed reflect its early stage.
14	27	42855278	Onco-fetal reprogramming and drug resistance in cancer	⚪	4.00	3	4	7	2	5	6	Single-cell genomics	High novelty; single-cell identification of a clinically consequential cancer subpopulation with defined TF drivers is genuinely novel. Preclinical stage limits near-term impact.
15	17	42854216	AI-based individualized therapy optimization for T2D	⚪	5.55	6	8	6	4	4	7	Retrospective cohort (n=533)	Massive population reach and meaningful clinical question; ranked lower than top tier because retrospective validation on 533 patients with AI outperforming guidelines cannot be acted upon yet. Prospective trial urgently needed.

Note: All remaining articles (16, 18–19, 21–26, 28–31, 33–37, 39–46) scored composite impact of ≤4.5, reflecting their exploratory stage, narrow population reach, or epidemiological/descriptive nature. They are watchlist-appropriate but do not rise to top-15 ranking.

---

PHASE 4 — Deep Dives

Deep dives requested for Articles 1, 2, and 3 per user instruction.

---

[HOOK] Polycystic ovary syndrome — PCOS — is one of the most common hormonal conditions on earth, affecting somewhere between 8 and 13 percent of reproductive-age women. That's potentially half a billion people. And quietly, almost invisibly, it dramatically raises the risk of type 2 diabetes and heart disease. The question many clinicians and patients face every day: what can women with PCOS actually do about that risk — and how much is enough?

[THE DISCOVERY] A new systematic review and network meta-analysis published in Human Reproduction Update analyzed 2,433 women across multiple randomized trials and found that lifestyle interventions — particularly exercise — improve key cardiometabolic markers in women with PCOS. Crucially, they identified a sweet spot for exercise dose: somewhere between 480 and 1,012 METs·min per week. That roughly translates to about 150 to 300 minutes of moderate-intensity exercise per week — the equivalent of brisk walking five days a week. That's a dose that most women can actually achieve.

[THE SCIENCE BEHIND IT] The researchers used network meta-analysis, a technique that lets you compare multiple different types of interventions simultaneously — diet, exercise, combination programs — even when they haven't been tested head-to-head in the same trial. This allows for more comprehensive rankings than a single comparison. The study synthesized data from many trials, covering a range of cardiometabolic outcomes including blood sugar control, lipid profiles, body composition, and blood pressure. The most important limitation to flag: the authors themselves rated the overall certainty of the evidence as low to very low, meaning that while the direction of effect is encouraging, we should hold these numbers with some humility — not dismiss them, but not over-prescribe from them either.

[WHO THIS HELPS] This directly helps women living with PCOS who face an elevated lifetime risk of type 2 diabetes and cardiovascular disease — risks that are often inadequately addressed in standard gynecologic care. It's particularly relevant for women who aren't candidates for or prefer not to use pharmacological interventions first. It also provides clearer guidance for primary care physicians, gynecologists, and endocrinologists who want to give specific, evidence-informed exercise advice rather than a vague "try to exercise more."

[THE REAL-WORLD IMPACT] If these findings are adopted into clinical practice, they shift the conversation from general lifestyle advice toward dose-specific exercise prescriptions for PCOS. A physician could now say: aim for at least 480 METs·min per week, which is achievable through structured, moderate exercise — and the data suggests broader benefits across multiple metabolic outcomes at that dose. No new drugs. No new devices. No new referrals. Exercise prescriptions are cheap, safe, and scalable globally.

[WHAT WE STILL DON'T KNOW] The low evidence certainty is the real open question. We need larger, well-designed randomized trials with consistent outcome measures and standardized exercise protocols to move from "promising signal" to "confident recommendation." We also don't know whether these benefits persist long-term, or how they interact with other PCOS treatments like metformin or GLP-1 receptor agonists.

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: Moderate
• Translation Speed: 2–5 years (exercise prescriptions can be implemented now, but guideline-level adoption needs higher certainty evidence)
• Barrier Analysis: No regulatory or cost barriers. Awareness is the primary barrier — clinicians and patients may not appreciate that dose matters. Equity concern: women without access to structured exercise programs, gym facilities, or safe outdoor spaces may not be able to achieve the target dose without support.

[CALL TO ACTION / CLOSING] For women with PCOS, exercise isn't just a wellness suggestion — at the right dose, it may be among the most powerful tools available to reduce the risk of diabetes and heart disease. The science is pointing us toward a number. Now we need the healthcare system to start prescribing it.

---

[HOOK] Imagine getting a CT scan for an unrelated reason — a kidney stone, maybe, or stomach pain — and your radiologist spots something on your adrenal gland. This happens to roughly 3 to 7 percent of everyone who gets an abdominal scan. Most of these so-called "incidentalomas" turn out to be nothing dangerous. But a meaningful subset of them silently pump out excess cortisol — just enough to quietly damage the heart, raise blood sugar, and elevate blood pressure. The clinical challenge: how do you find those patients?

[THE DISCOVERY] A new systematic review and hierarchical SROC meta-analysis published in Endocrine Practice evaluated the diagnostic performance of the common biochemical screening tests used to detect mild autonomous cortisol secretion (MACS) in patients with adrenal incidentalomas. The study analyzed data from 1,420 patients and compared tests including the 1-mg overnight dexamethasone suppression test — the standard first-line screen — alongside other biochemical markers. The overarching finding: no single test performs well enough to be used in isolation. Positive results require clinical context and confirmatory evaluation.

[THE SCIENCE BEHIND IT] The researchers used a hierarchical Summary Receiver Operating Characteristic (SROC) model — a sophisticated meta-analytic approach that accounts for the trade-off between sensitivity and specificity across different studies and different test thresholds. This is particularly appropriate for diagnostic accuracy studies where threshold effects are a major source of heterogeneity. With n=1,420, this is a reasonably powered synthesis. The main limitation is that the evidence is abstract-only and the absolute diagnostic performance figures — the key numbers clinicians need — are not available without full-text access, limiting the ability to derive precise clinical decision thresholds from this summary alone.

[WHO THIS HELPS] This is directly relevant to three groups of clinicians: endocrinologists who manage adrenal incidentalomas; radiologists who identify them and need to flag the appropriate next steps; and primary care physicians who receive incidentaloma reports and must decide whether to refer. Given that millions of CTs are performed globally each year and a consistent fraction reveal incidentalomas, this affects an enormous clinical workflow — even if the final number of patients with true MACS is smaller.

[THE REAL-WORLD IMPACT] MACS is associated with increased rates of hypertension, type 2 diabetes, dyslipidemia, and cardiovascular events — conditions that are treatable and potentially reversible if the excess cortisol production is identified and managed, either through adrenalectomy or medical therapy. A clearer understanding of which screening tests perform best — and under what circumstances — helps clinicians avoid both over-investigation (expensive, anxiety-provoking) and under-detection (missing a treatable cause of cardiometabolic disease). The finding that all positive results need clinical context is itself clinically important: it argues against algorithmic, reflex testing without an accompanying clinical judgment framework.

[WHAT WE STILL DON'T KNOW] The key unanswered question is: what are the actual sensitivity and specificity numbers for each test, and which one performs best in which pre-test probability setting? Without full-text access to the detailed SROC curves, we cannot answer this. The field also needs better evidence on whether treating screen-detected MACS actually reduces cardiovascular events — the clinical outcome that ultimately matters.

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: Moderate
• Translation Speed: 2–5 years (existing tests; guidance change is adoption-dependent)
• Barrier Analysis: No new technology required. The primary barrier is awareness among generalists and radiologists that incidentaloma follow-up should include formal MACS screening. Reimbursement for biochemical testing is generally established in developed health systems. Equity concern: incidentaloma detection is itself biased toward populations with high CT utilization — screening programs may disproportionately benefit higher-income, imaging-rich health systems.

[CALL TO ACTION / CLOSING] An adrenal incidentaloma is not just a radiological footnote — for a meaningful subset of patients, it is the first sign of a silent hormonal condition that is silently damaging their heart and metabolism. Better screening protocols, built on rigorous diagnostic accuracy evidence, are how we find those patients before the damage compounds.

---

[HOOK] Roughly half a million people undergo coronary artery bypass grafting — CABG — every year in the United States alone. After that major surgery, cardiac rehabilitation is one of the most evidence-backed interventions in all of cardiovascular medicine, proven to reduce re-hospitalization, improve fitness, and extend life. But most patients never complete it. The barriers are real: travel, cost, time away from work, physical limitations. Home-based cardiac rehab has emerged as a promising solution. The question this new meta-analysis tries to answer is: does it actually work as well?

[THE DISCOVERY] A systematic review and meta-analysis published in Heart & Lung pooled evidence from studies comparing home-based cardiac rehabilitation (HBCR) to centre-based cardiac rehabilitation (CBCR) specifically in patients who had undergone CABG. With a combined sample of 991 patients, the researchers examined functional capacity — how well patients can exercise — as well as psychological outcomes and health-related quality of life. Their honest conclusion: the evidence remains limited and inconclusive. No firm conclusions can be drawn.

[THE SCIENCE BEHIND IT] This is a systematic review with meta-analysis, a study design that sits at the top of the evidence hierarchy. However, quality only follows if the underlying studies are sufficient in number and rigor — and here they were not. The analysis was constrained by a small number of qualifying studies and substantial heterogeneity, meaning the individual studies differed enough in their protocols, patient populations, and outcome measures that pooling them introduces real uncertainty. Functional capacity data trended toward equivalence between HBCR and CBCR, which is in line with broader cardiac rehab literature. But the psychological and quality-of-life outcomes — arguably the most important for patients — were inconclusive. Abstract-only access further limits interpretation. The main limitation is that a meta-analysis is only as strong as the studies within it, and the CABG-specific evidence base is thin.

[WHO THIS HELPS] In its current state, this review helps three groups in different ways. For patients who cannot access centre-based rehabilitation due to distance, mobility limitations, or schedule constraints, it provides reassurance that home-based approaches are probably not inferior for physical outcomes — even if not definitively proven equivalent. For healthcare systems, it supports piloting and funding HBCR programs, particularly in rural or low-resource settings. For researchers, it clearly identifies where the evidence gap lies: patient-reported and psychosocial outcomes after CABG in home settings.

[THE REAL-WORLD IMPACT] If HBCR is eventually confirmed as equivalent to CBCR for CABG patients, the implications are significant. Participation in cardiac rehab remains stubbornly low — often under 30% of eligible patients in real-world settings. Home-based programs could dramatically expand access, particularly for older adults, women (who participate at lower rates), rural patients, and lower-income patients for whom transportation and time costs are prohibitive. Reducing barriers to rehab participation after bypass surgery could prevent thousands of readmissions and deaths annually.

[WHAT WE STILL DON'T KNOW] The central uncertainty is whether HBCR and CBCR produce equivalent patient-reported outcomes — mood, anxiety, quality of life — in CABG patients specifically. We also don't know which subgroups benefit most from each delivery model, what digital or remote monitoring technologies optimize HBCR adherence, or whether equivalence holds over one to three years post-surgery rather than just the initial rehabilitation period.

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: Low to Moderate (equivalence is plausible but unproven; more rigorous trials needed)
• Translation Speed: 2–5 years (with new adequately powered RCTs; existing HBCR infrastructure is already partially in place)
• Barrier Analysis: Infrastructure exists in many health systems for phone- and app-based monitoring that could support HBCR. Regulatory barriers are low. Reimbursement is the primary barrier in many systems — HBCR is not universally covered. Equity opportunity is significant: the populations most likely to benefit from home access are those currently least served by centre-based programs.

[CALL TO ACTION / CLOSING] Cardiac rehabilitation after bypass surgery saves lives — but only if patients can actually get to it. Home-based rehab may be the key to reaching the patients most at risk of dropping out, and the research community owes them a definitive answer.